Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Cash flows from operating activities
Net loss	$ (2,959,993)	$ (3,093,402)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation	9,192	9,192
Amortization	212,406	212,406
Lease expense (benefit)	2,141	(2,851)
Stock-based compensation – employees	393,300	713,550
Stock-based compensation – non-employees	162,000
Non-cash interest expense	1,595,145	1,382,764
Non-cash interest expense – related parties	203,510	227,439
Foreign exchange (gain) loss	(63,947)	51,540
Changes in operating assets and liabilities which (used) provided cash
Other receivable	75,107	(1,053)
Accounts payable	55,075	(3,698)
Accounts payable – related parties	8,347
Accrued expenses	62,400	89,858
Net cash used in operating activities	(245,317)	(414,255)
Cash flows used in investing activities
Advances to CEN Biotech Ukraine LLC		(120,000)
Cash flows provided by financing activities
Issuance of convertible notes	250,000	533,034
Repayment of convertible notes		(6,000)
Issuance of convertible notes – related parties		20,000
Net cash provided by financing activities	250,000	547,034
Net increase in cash and cash equivalents	4,683	12,779
Cash and cash equivalents, beginning of period	3,757	3,193
Cash and cash equivalents, end of period	8,440	15,972
Supplemental cash flows disclosures
Cash paid for interest	8,000	33,913
Non-cash transactions - investing and financing activities
Issuance of common stock - settlement of accrued liability	$ 58,500